Literature DB >> 7942721

Surveillance in Lynch syndrome: how aggressive?

S J Lanspa1, J X Jenkins, R J Cavalieri, T C Smyrk, P Watson, J Lynch, H T Lynch.   

Abstract

OBJECTIVE: To identify colorectal cancers occurring after colonoscopic screening in patients at risk for Lynch syndrome.
METHODS: All cancers in Lynch syndrome families on file at the Creighton University Hereditary Cancer Institute were reviewed for history of prior colonoscopy.
RESULTS: Of 225 individuals with 313 colon cancers, six patients from different families had colon cancers arising within 4 1/2 yr of colonoscopic surveillance. Another 17 patients had metachronous colon cancers within 5 yr of resection of their first colon cancer.
CONCLUSION: Of 225 colorectal cancer patients from Lynch syndrome families, 10.2% of patients had colorectal cancer within 5 yr of colonoscopy or colon resection. In Lynch syndrome, the potential for interval neoplasms and the malignant potential of missed diminutive adenomas may differ from cases in the general population.

Entities:  

Mesh:

Year:  1994        PMID: 7942721

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

1.  Colonoscopy in Lynch syndrome: the need for a new quality score.

Authors:  Jurjen J Boonstra; Wouter H de Vos Tot Nederveen Cappel; Alexandra M J Langers; Hedwig van der Sluis; James H Hardwick; Hans F A Vasen
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

Review 2.  Genetic susceptibility to non-polyposis colorectal cancer.

Authors:  H T Lynch; A de la Chapelle
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

3.  Colorectal cancer screening in women with endometrial cancer: are we following the guidelines?

Authors:  Marvin Mohan Singh; Emily Singh; Heather Miller; Williamson B Strum; Walter Coyle
Journal:  J Gastrointest Cancer       Date:  2012-06

4.  Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation.

Authors:  F E M Rijcken; H Hollema; J H Kleibeuker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 5.  Milestones of Lynch syndrome: 1895-2015.

Authors:  Henry T Lynch; Carrie L Snyder; Trudy G Shaw; Christopher D Heinen; Megan P Hitchins
Journal:  Nat Rev Cancer       Date:  2015-02-12       Impact factor: 60.716

Review 6.  Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients.

Authors:  Kristen M Drescher; Poonam Sharma; Henry T Lynch
Journal:  Clin Dev Immunol       Date:  2010-06-10

Review 7.  Surgical treatment of hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome).

Authors:  Miguel A Rodriguez-Bigas; Gabriela Möeslein
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

8.  Rapid Disease Progression of Liver Metastases following Resection in a Liver-Transplanted Patient with Probable Lynch Syndrome - A Case Report and Review of the Literature.

Authors:  Noelle Suemi Wassano; Francisco Sergi; Gustavo Ferro; Tércio Genzini; Renata D'Alpino Peixoto
Journal:  Case Rep Oncol       Date:  2017-03-15

9.  Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome.

Authors:  Robert W Haile; Henry T Lynch; Megan P Hitchins; Ingrid P Vogelaar; Kevin Brennan; Sigurdis Haraldsdottir; Nianmin Zhou; Brock Martin; Rocio Alvarez; Xiaopu Yuan; Sungjin Kim; Maha Guindi; Andrew E Hendifar; Matthew F Kalady; Jennifer DeVecchio; James M Church; Albert de la Chapelle; Heather Hampel; Rachel Pearlman; Maria Christensen; Carrie Snyder; Stephen J Lanspa
Journal:  BMJ Open Gastroenterol       Date:  2019-05-28

10.  Hereditary cancer registries improve the care of patients with a genetic predisposition to cancer: contributions from the Dutch Lynch syndrome registry.

Authors:  Hans F A Vasen; Mary E Velthuizen; Jan H Kleibeuker; Fred H Menko; Fokke M Nagengast; Annemieke Cats; Andrea E van der Meulen-de Jong; Martijn H Breuning; Anne J Roukema; Inge van Leeuwen-Cornelisse; Wouter H de Vos Tot Nederveen Cappel; Juul T Wijnen
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.